Mirus Capital AdvisorsMirus Capital Advisors

VuCOMP Announces Sale of M-Vu to iCAD, Inc.

vucomp

VuCOMP, Inc., leading developer of advanced computer vision systems for the detection of breast cancer, announced that it has sold its M-Vu Breast Density software to iCAD, Inc.

“Our sale of M-Vu Breast Density will enable VuCOMP to focus our resources on the development of CAD for breast tomosynthesis”

The purchase and sale agreement includes the transfer of the breast density technology and associated service contracts, but does not include the computer-aided detection platforms, which will remain with VuCOMP. Under the agreement, VuCOMP will continue to sell the breast density product.

“Our sale of M-Vu Breast Density will enable VuCOMP to focus our resources on the development of CAD for breast tomosynthesis,” said Jim Pike, President and Chief Technology Officer, VuCOMP. “We are committed to bringing to market the first CAD solution for breast tomosynthesis, and continuing to develop our advanced CAD solutions.”

VuCOMP has already submitted its premarket approval application for CAD for breast tomosynthesis to the FDA, and anticipates a product launch no later than the fourth quarter of 2015.

VuCOMP and iCAD will work collaboratively to ensure a seamless transition of service and support for existing M-Vu Breast Density customers to iCAD.

About VuCOMP, Inc.

VuCOMP, Inc. leads the way in setting a new standard for computer-aided detection. The company is dedicated exclusively to developing advanced cancer detecting technologies. VuCOMP’s engineering team has worked together since 1986, pioneering some of the world’s most advanced computer vision systems. For more information, please visit www.vucomp.com.

Back to Transactions